BIS outlines how pharmaceutical companies can seek company-specific onshoring agreements to reduce new 100% Section 232 tariffs on patented drugs and ingredients.
| less than a minute read
BIS Issues Procedures for Onshoring Agreements to Mitigate 100% Tariffs on Patented Pharmaceuticals
Get in touch
Get in touch
Get in touch
Get in touch
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-08-13-17-31-05-370-6a7dff59254a1a438c04847f.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-08-13-17-30-24-631-6a7dff305d5875e92599b3bd.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-08-13-13-11-12-930-6a7dc270226bd6f89e20adbb.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-08-13-13-10-12-561-6a7dc234ab75b4d21322f54f.jpg)